Urology Times staff

In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

“We found that men with an elevated FSH but a normal semen test were more likely to have a decline in their sperm concentration and their total motile sperm count over time…when compared to men also starting with the normal semen test but with a normal FSH,” says Joshua Halpern, MD.

“It’s an exciting time in UTUC,” says Joseph Jacob, MD.

“A ureteral stent can be bothersome, but it’s quite variable. Some people don’t even feel the stent and some people have severe symptoms,” says Johnathan Harper, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Based on the recommendation of an independent Data Monitoring Committee, the CheckMate-901 trial is continuing in order to evaluate the other primary and secondary endpoints.

Katie Murray, DO, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube.

In the phase 3 SPOTLIGHT trial, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.

“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.

“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.

“SWIU has just, in my humble opinion, gained incredible traction in the last few years, and it's a really great organization,” says Kara L. Watts, MD.

The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.

“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.

“I had long thought that vitamin D deficiency could be a risk factor for prostate cancer,” says Adam B. Murphy, MD, MBA, MSCI.

Tanya Dorff, MD, discusses findings from a phase 1 clinical trial that explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer.

"Anatomic radical prostatectomy really transformed radical prostatectomy from a very morbid operation with high risk, performed rarely, to one that became a commonly utilized treatment for prostate cancer," says Christopher L. Amling, MD, FACS.

“I think it's really important to understand the role of prevention and early detection,” says Michael Lutz, MD.

Zeyad Schwen, MD, highlights 5 studies in prostate cancer being presented at the 2022 American Urological Association Annual Meeting.

Nima Almassi, MD, highlights 5 studies in bladder cancer being presented at the 2022 American Urological Association Annual Meeting.

Amy Krambeck, MD, highlights 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting.

“While we have these young men in our offices, we need to try and engage them for all of the necessary screening opportunities that will improve the quality of their lives moving forward,” says Michael Lutz, MD, in this podcast episode.

“For the first time, we have 20-year follow-up data after the penile prosthesis,” says Mohit Khera, MD, MBA, MPH.

Amy M. Pearlman, MD, highlights 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Denise Asafu-Adjei, MD, MPH, discusses the development of microsurgical testicular sperm extraction.

"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.

“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.

"This non face-to-face care coordination done 'incident to' to the provider...is reimbursable through chronic care management codes," says Shirley Lee, CRNP-FNP, MPH.

The sNDA is based on findings from the phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT boosted overall survival in patients with mHSPC.

“Getting people to work together towards a common goal is really, really important in alleviating the imposter syndrome,” says Toby C. Chai, MD.